Molecular Devices Becomes Global Distributor of IonFlux
News May 28, 2013
Molecular Devices® announced it has made an agreement with Fluxion Biosciences to become global distributor for the IonFlux™ portfolio of instrumentation and consumables. Molecular Devices will also provide support for all IonFlux Systems users through its recently expanded team of Application Specialists.
The IonFlux Systems offer an unrivalled level of simplicity for electrophysiology. Combined with low running costs, this makes the systems an ideal solution for laboratories in both academic and industrial settings. The IonFlux 16 Electrophysiology System is capable of delivering results from up to 64 test compounds per run, while the IonFlux HT Platform can deliver results from up to 256 test compounds per run.
Jeff Jensen, CEO of Fluxion, commented: “Molecular Devices’ long history in the electrophysiology field, combined with the expertise of its applications support team, means that they are ideally placed to support scientists working with IonFlux Systems. We are delighted that they will be taking responsibility for distributing the line worldwide.”
Kevin Chance, President of Molecular Devices, said: “The IonFlux Systems are an excellent complement to our existing line of electrophysiology products, which includes IonWorks Barracuda® and IonWorks Quattro™ Automated Systems with Population Patch Clamp™ Technology, PatchXpress® 7000A and the Axon® line of Conventional Electrophysiology Systems. The simplicity of the IonFlux Systems enables a broad range of scientists to access electrophysiology and ion channel research, making them a great addition to the Molecular Devices offering.
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Big-Data Analysis Points Toward New Drug Discovery MethodNews
A research team has developed a computational method to systematically probe massive amounts of open-access data to discover new ways to use drugs, including some that have already been approved for other uses.
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018
18th International Conference and Exhibition on Analytical & Bioanalytical Chromatographic Techniques
Nov 02 - Nov 03, 2017